Last reviewed 2026-06-10 · How we verify

Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine — Treatment Landscape & Competitive Intelligence

Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent b

Marketed treatment landscape

Approved drugs treating Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Pfizer · 1 drug in Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine:

• Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine treatment updates — RSS
• Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine treatment updates — Atom
• Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine treatment updates — JSON

Cite this brief

Drug Landscape (2026). Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-any-covid-19-vaccine-when-administered-at-least-2-months-after-the-completion-of-primary-vaccination-or-any-subsequent-booster-dose-with-any-covid-19-vaccine-and-at-least-2-months-after-administration-of-a-prior-booster-dose-with-any-covid-19-vaccine. Accessed 2026-06-10.

Related

• Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing